18794-95-1

Basic information

• Product Name: Butanoic acid, 2-[2-(2-Methoxyphenyl)hydrazinylidene]-3-oxo-, ethyl ester
• Synonyms: Butanoic acid, 2-[2-(2-Methoxyphenyl)hydrazinylidene]-3-oxo-, ethyl ester
• CAS NO: 18794-95-1
• Molecular Formula: C₁₃H₁₆N₂O₄
• Molecular Weight: 264.27714
• Mol File: 18794-95-1.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Butanoic acid, 2-[2-(2-Methoxyphenyl)hydrazinylidene]-3-oxo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 2-[2-(2-Methoxyphenyl)hydrazinylidene]-3-oxo-, ethyl ester(18794-95-1)
• EPA Substance Registry System: Butanoic acid, 2-[2-(2-Methoxyphenyl)hydrazinylidene]-3-oxo-, ethyl ester(18794-95-1)

Safety Data

• Hazardous Substances Data: 18794-95-1(Hazardous Substances Data)

Upstream product

• 141-97-9 ethyl acetoacetate 
• 104-94-9 4-methoxy-aniline 
• 4346-59-2 para-methoxyphenyldiazonium chloride 

Downstream Products

• 77336-02-8 4-[(4-Methoxy-phenyl)-hydrazono]-5-methyl-2-(pyridine-4-carbonyl)-2,4-dihydro-pyrazol-3-one 
• 70079-59-3 2-(4,6-dimethyl-pyrimidin-2-yl)-5-methyl-2H-pyrazole-3,4-dione 4-[(4-methoxy-phenyl)-hydrazone] 
• 132577-12-9 4-[(4-Methoxy-phenyl)-hydrazono]-5-methyl-2-phthalazin-1-yl-2,4-dihydro-pyrazol-3-one 
• 123565-82-2 ethyl 5-cyano-1-(4-methoxyphenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate 
• 112517-60-9 2-(3,5-Dinitro-benzoyl)-4-[(4-methoxy-phenyl)-hydrazono]-5-methyl-2,4-dihydro-pyrazol-3-one 
• 84384-61-2 2-[2-(2,4-Dinitro-phenyl)-acetyl]-4-[(4-methoxy-phenyl)-hydrazono]-5-methyl-2,4-dihydro-pyrazol-3-one 
• 131628-04-1 3-{4-[(4-Methoxy-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl}-N-naphthalen-2-yl-3-oxo-propionamide 
• 5669-77-2 3-methyl-isoxazole-4,5-dione 4-[(4-methoxy-phenyl)-hydrazone] 
• 136920-71-3 8-Methoxy-3-methyl-1-phenyl-1H-pyrazolo[4,3-c]cinnoline 
• 136920-59-7 6-Methoxy-3-(1-{[4-phenyl-3H-thiazol-(2Z)-ylidene]-hydrazono}-ethyl)-cinnolin-4-ol 

Relevant articles and documents

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists

Chemokine receptor 2 (CXCR2) is the receptor of glutamic acid–leucine–arginine sequence-contained chemokines CXCs (ELR+ CXCs). In recent years, CXCR2-target treatment strategy has come a long way in cancer therapy. CXCR2 antagonists could block

Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors

A series of 7-azaindole derivatives bearing the dihydropyridazine scaffold were synthesized and evaluated for their c-Met kinase inhibitory, and antiproliferative activity against 4 cancer cell lines (HT29, A549, H460, U87MG) were evaluated in?vitro. Most compounds showed moderate to excellent potency. Compared to foretinib, the most promising analog 34 (c-Met IC50: 1.06?nM, a multitarget tyrosine kinase inhibitor) showed a 6.4-, 7.8-, and 3.2-fold increase in activity against HT29, A549, and H460?cell lines, respectively. Structure activity relationship studies indicated that mono-EWGs (such as R2?=?F) at 4-position of moiety D was a key factor in improving the antitumor activity.

Microwave assisted synthesis and biological activity of 4-(2-(aryl substituted) hydrazono)-1-(2-(p-tolyloxyacetyl)-3-methyl-1H-pyrazol- 5-one

A novel series of 4-(2-(aryl substituted) hydrazono)-1-(2-(p-tolyloxy) acetyl)-3-methyl- 1H-pyrazol-5-ones 3(a-j) was prepared by the reaction of ethyl-2-arylhydrazono -3- oxobutyrate and p-tolyloxyacethydrazide under microwave irradiation. The structures of the synthesized compounds were established by their spectral and analytical data. All the new compounds were screened for their antibacterial and antifungal activity.